Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
about
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesPost-remission therapy for acute myeloid leukemiaMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.The indications for allogeneic stem cell transplantation in myeloid malignancies.Clinical analysis and interpretation of cancer genome dataChromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.Minimal residual disease in acute myeloid leukaemiaMRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.FLT3 and NPM-1 mutations in a cohort of acute promyelocytic leukemia patients from IndiaImproved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia.A multigene array for measurable residual disease detection in AML patients undergoing SCTDevelopment of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.Comparative analysis of different approaches to measure treatment response in acute myeloid leukemiaProfiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Measurements of treatment response in childhood acute leukemia.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of lifeAcute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 MarkerPretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaDiagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Functional heterogeneity of genetically defined subclones in acute myeloid leukemiaPrognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics.How to manage high-risk acute myeloid leukemia.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.
P2860
Q26770394-C92D76AE-DE20-4729-965D-93D48FDF9291Q26995867-F9A0395E-54B4-498E-9857-68C8B54191ECQ26998811-C969EAD8-845A-4984-9A3E-42DA3F3D1BFCQ28073464-428F7383-EA90-4D43-BBEC-2AA268485249Q28087291-7358F167-A136-4159-8A92-0BB504690A57Q30234914-78AA2059-C081-4ACB-BD1D-FC64F6C218B1Q30316611-5C8DC2DD-B5A8-4387-8163-882EA30EC44BQ30617093-A475873C-1407-47D8-81D4-B9428377D9D6Q33822055-E4335433-5016-4147-B629-97834A051628Q33832709-267D928F-9AFB-482E-9D40-2F39BAE7DC1EQ33840223-F9731972-9631-4587-B0EF-137412019FE3Q33877213-3BCDCD84-6D59-4180-A259-4E17C705BBB0Q33931553-1C927949-D746-477D-8956-B05E5A18D9C3Q33978907-007DD3B9-77FD-425C-9E90-A74009810BCFQ34086334-1FCF5153-04BC-4DCC-8099-C7D38611BF1DQ34179265-BF02236D-750E-47F5-AB49-1591F914DB27Q34227693-7E7AA4D4-7D63-4CC0-9B94-CA585AF4E38BQ34364350-EE1B3A3A-BD0E-4559-AA49-64B9C87353DEQ34494573-8134AAF0-06E8-4E1A-8E53-EAD880224561Q34620761-6C7420DC-8862-4ACD-81D6-2AC82FEFC755Q34715598-218351D3-F5F1-4605-9A0B-6D1EBA6EF055Q34784732-464E52EB-2F20-4B24-BBB5-B32721E8989DQ35582360-1026108D-813A-4BDC-B064-B691FB08EA64Q35971837-7746A0A8-0F1D-4984-BA09-8E6EE89A9C22Q36290737-7F23AA0B-B652-4690-A089-D1F2D25A9258Q36322776-5F0E14A5-75E2-411F-A0D2-A192DD67AE75Q36513773-A112E371-B094-4140-96A2-3BE5324D423EQ36561772-18010F13-49CB-48D2-A098-C71190B5504FQ36633055-CE51EA9D-3BE3-4A47-B769-9F7D9843204FQ36849666-DBFA4ADA-7E23-46D9-93BB-C39FF73A8C5CQ36862461-300A34F9-9430-4C66-BB80-213BFBD5808AQ37084121-18023BD8-966D-453E-A78C-39DA19196C53Q37141503-F614A978-C900-4CC7-A284-2AEC6572C432Q37144451-9B5F4722-0C08-4700-87FD-86A2F2C3B8F1Q37270982-5E77917F-A509-4F2E-9D5C-04ABCDE9A7F1Q37624593-FB89D51A-3364-44E0-BF1B-705CDA8B3A60Q37698123-3EB543F8-AB7C-4DF3-8E83-1CCC71CB3A8DQ37954583-C82AEE39-0CC5-4927-BB68-4F33EC802733Q37960820-425DEC9C-B37E-4956-BE79-2AF252E2DFD0Q38022075-10680D17-B5FA-40F5-8DFA-F980ADD102C6
P2860
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Monitoring of minimal residual ...... myeloid leukemia study group.
@en
Monitoring of minimal residual ...... myeloid leukemia study group.
@nl
type
label
Monitoring of minimal residual ...... myeloid leukemia study group.
@en
Monitoring of minimal residual ...... myeloid leukemia study group.
@nl
prefLabel
Monitoring of minimal residual ...... myeloid leukemia study group.
@en
Monitoring of minimal residual ...... myeloid leukemia study group.
@nl
P2093
P50
P356
P1476
Monitoring of minimal residual ...... myeloid leukemia study group.
@en
P2093
Andrea Corbacioglu
Arnold Ganser
Daniela Späth
David Nachbaur
Detlef Haase
Florian Tschürtz
Gerhard Held
Gudrun Göhring
Hans-Günther Mergenthaler
Helmut R Salih
P304
P356
10.1200/JCO.2011.35.0371
P407
P577
2011-05-09T00:00:00Z